Dexcom G7 is clinically proven to improve glycemic outcomes 1-5

• 1% A1C reduction after 12 weeks 1,2,5
• 80% fewer events of severe hypoglycemia vs. conventional therapy 6
• Features to reduce rebound hyper- and hypoglycemia 7,8

Patients using DexcomCGM resulted in:
35% (~$358 PPPM) reduced diabetesrelated inpatient admission costs*, 9
~50% reduced diabetesrelated inpatient visits†,10

CGM = continuous glucose monitoring; PPPM = per patient per month; T2D = type 2 diabetes.
*Retrospective analysis of Optum Research Database administrative claims data for patients with T2D (N = 571) after initiation of Dexcom CGM. † Retrospective analysis of US healthcare claims data using Optum’s Clinformatics® database in patients with T2D on intensive insulin therapy who initiated Dexcom CGM. Diabetes-related events were assessed 12 months pre- and post-index.

1 Beck RW, et al. JAMA. 2017;317(4):371-378. 2 Beck RW, et al. Ann Intern Med. 2017;167(6):365-374. 3 Martens T, et al. JAMA. 2021;325(22):2262-2272. 4 Laffel LM, et al. JAMA. 2020;323(23):2388-2396. 5 Welsh JB, et al. J Diabetes Sci Technol. 2024;18(1):143-147. 6 Lind M, et al. JAMA. 2017;317(4):379-387. 7 Puhr S, et al. Diabetes Technol Ther. 2019;21(4):155-158. 8 Acciaroli G, et al. J Diabetes Sci Technol. 2022;16(3):677-682. 9 Norman GJ, et al. Diabetes Technol Ther. 2022;24(7):520-524. 10 Hannah KL, et al. Adv Ther. 2024;41(6):2299-2306.

BRIEF SAFETY STATEMENT: Failure to use the Dexcom G7 Continuous Glucose Monitoring System (G7) and its components according to the instructions for use provided with your device and available at https://www.dexcom.com/safety-information and to properly consider all indications, contraindications, warnings, precautions, and cautions in those instructions for use may result in you missing a severe hypoglycemia (low blood glucose) or hyperglycemia (high blood glucose) occurrence and/or making a treatment decision that may result in injury. If your glucose alerts and readings from the G7 do not match symptoms, use a blood glucose meter to make diabetes treatment decisions. Seek medical advice and attention when appropriate, including for any medical emergency.

Dexcom and any related logos and design marks are either registered trademarks or trademarks of
Dexcom, Inc. in the United States and/or other countries.
©2025 Dexcom, Inc. All rights reserved. MAT-101